Gyrodyne (NASDAQ:GYRO – Get Free Report) and Cushman & Wakefield (NYSE:CWK – Get Free Report) are both finance companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.
Insider and Institutional Ownership
71.4% of Gyrodyne shares are held by institutional investors. Comparatively, 95.6% of Cushman & Wakefield shares are held by institutional investors. 12.1% of Gyrodyne shares are held by company insiders. Comparatively, 0.5% of Cushman & Wakefield shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Profitability
This table compares Gyrodyne and Cushman & Wakefield’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Gyrodyne | N/A | N/A | N/A |
| Cushman & Wakefield | 2.23% | 14.69% | 3.60% |
Risk & Volatility
Analyst Recommendations
This is a summary of recent ratings and price targets for Gyrodyne and Cushman & Wakefield, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Gyrodyne | 0 | 0 | 0 | 0 | 0.00 |
| Cushman & Wakefield | 0 | 6 | 5 | 0 | 2.45 |
Cushman & Wakefield has a consensus price target of $17.44, indicating a potential upside of 6.15%. Given Cushman & Wakefield’s stronger consensus rating and higher possible upside, analysts clearly believe Cushman & Wakefield is more favorable than Gyrodyne .
Valuation & Earnings
This table compares Gyrodyne and Cushman & Wakefield”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Gyrodyne | N/A | N/A | N/A | N/A | N/A |
| Cushman & Wakefield | $9.45 billion | 0.40 | $131.30 million | $0.96 | 17.12 |
Cushman & Wakefield has higher revenue and earnings than Gyrodyne .
Summary
Cushman & Wakefield beats Gyrodyne on 9 of the 10 factors compared between the two stocks.
About Gyrodyne
Gyrodyne, LLC owns and manages a diversified portfolio of real estate properties comprising office, industrial and service-oriented properties in the New York metropolitan area. Gyrodyne owns a 63 acre site approximately 50 miles east of New York City on the north shore of Long Island, which includes industrial and office buildings and undeveloped property which is the subject of plans to seek value-enhancing entitlements. Gyrodyne also owns a medical office park in Cortlandt Manor, New York which is also the subject of a subdivision application. Gyrodyne's common shares are traded on the NASDAQ Stock Market under the symbol GYRO.
About Cushman & Wakefield
Cushman & Wakefield Plc engages in the provision of commercial real estate services. It operates through the following geographical segments: Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific (APAC). The Americas segment consists of operations located in the United States, Canada and key markets in Latin America. The EMEA segment includes operations in the UK, France, Netherlands and other markets in Europe and the Middle East. The APAC segment comprises of operations in Australia, Singapore, China and other markets in the Asia Pacific region. The company was founded in 1917 and is headquartered in London, the United Kingdom.
Receive News & Ratings for Gyrodyne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyrodyne and related companies with MarketBeat.com's FREE daily email newsletter.
